GLP-1 therapies are rapidly reshaping the landscape of type 2 diabetes and obesity — two of the most prevalent and costly chronic conditions in the workforce. While these therapies offer significant clinical benefits, they also introduce substantial pharmacy spend, long-term utilization considerations and concerns about long-term value. This employer action brief offers practical, evidence-based guidance to evaluate and manage GLP-1 coverage in a way that balances affordability, access, equity, and measurable value, and includes employer coverage models, questions to ask your vendors, sample contract language and how to present these challenges to leadership.